每周股票复盘：中国医药（600056）子公司布洛芬片通过一致性评价

Group 1 - The stock price of China Medical (600056) closed at 10.6 yuan on January 16, 2026, down 2.03% from 10.82 yuan the previous week, with a market cap of 15.856 billion yuan, ranking 6th in the pharmaceutical commercial sector and 1330th in the A-share market [1] - The company announced that it will hold the 2024 annual general meeting on May 16, 2025, to review the issuance of corporate bonds and short-term financing bills, and has received approval from the China Securities Regulatory Commission to issue bonds totaling no more than 2 billion yuan [1][3] - The approval for bond issuance is valid for 24 months from the date of registration, allowing the company to issue in tranches during this period [1] Group 2 - The wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the Ibuprofen tablet, which has passed the consistency evaluation of generic drug quality and efficacy [2] - The sales revenue for Ibuprofen tablets in China is estimated to be approximately 113 million yuan in 2024, with the company's sales expected to be around 1.92 million yuan in 2025 [2] - Passing the consistency evaluation is expected to enhance the product's market competitiveness, although future sales remain uncertain [2]